[go: up one dir, main page]

CL2016003023A1 - “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct - Google Patents

“compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct

Info

Publication number
CL2016003023A1
CL2016003023A1 CL2016003023A CL2016003023A CL2016003023A1 CL 2016003023 A1 CL2016003023 A1 CL 2016003023A1 CL 2016003023 A CL2016003023 A CL 2016003023A CL 2016003023 A CL2016003023 A CL 2016003023A CL 2016003023 A1 CL2016003023 A1 CL 2016003023A1
Authority
CL
Chile
Prior art keywords
carbonyl
rorg
piperazin
modulators
substituted
Prior art date
Application number
CL2016003023A
Other languages
English (en)
Inventor
Hui Lei
Xin Ma
Feng Ren
Xichen Lin
Robert W Marquis Jr
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2016003023A1 publication Critical patent/CL2016003023A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE (BENCIL-PIPERAZIN-1-IL)(TETRAHIDROFURAN-CARBONIL O TETRAHIDROPIRAN-CARBONIL) SUSTITUIDO, MODULADORES RORG, A UNA COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE Y ESPONDILITIS ANQUILOSANTE.
CL2016003023A 2014-05-28 2016-11-24 “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct CL2016003023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014078701 2014-05-28

Publications (1)

Publication Number Publication Date
CL2016003023A1 true CL2016003023A1 (es) 2017-04-21

Family

ID=54698095

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003023A CL2016003023A1 (es) 2014-05-28 2016-11-24 “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct

Country Status (18)

Country Link
US (1) US9868724B2 (es)
EP (1) EP3148987B1 (es)
JP (1) JP6522665B2 (es)
KR (1) KR20170008852A (es)
CN (1) CN107001342B (es)
AU (1) AU2015267911B2 (es)
CA (1) CA2953637C (es)
CL (1) CL2016003023A1 (es)
CR (1) CR20160549A (es)
DO (1) DOP2016000311A (es)
EA (1) EA032272B1 (es)
ES (1) ES2716966T3 (es)
IL (1) IL248983A0 (es)
MX (1) MX2016015631A (es)
PE (1) PE20170137A1 (es)
PH (1) PH12016502331A1 (es)
SG (1) SG11201609722UA (es)
WO (1) WO2015180614A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35174A (es) 2012-12-06 2014-06-30 Glaxo Group Ltd Nuevos moduladores del receptor huerfano gamma relacionado con retinoides
EP3148975B1 (en) 2014-05-28 2018-11-28 GlaxoSmithKline Intellectual Property Development Limited Piperazine derivatives as ror-gamma modulators
EA032272B1 (ru) 2014-05-28 2019-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новые соединения
CN106660999A (zh) 2014-05-28 2017-05-10 葛兰素史密斯克莱知识产权发展有限公司 新化合物
BR112019000486A2 (pt) 2016-07-13 2019-04-24 Leo Pharma A/S composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
PE20141637A1 (es) 2011-04-28 2014-11-20 Japan Tobacco Inc Compuesto de amida y aplicacion farmaceutica para el mismo
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
HK1199839A1 (en) * 2011-09-09 2015-07-24 New York University Amido compounds as ror-gamma-tmodulators and uses thereof
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013100027A1 (ja) * 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
CN104379559B (zh) 2012-04-27 2016-11-09 葛兰素集团有限公司 化合物
JO3215B1 (ar) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
AU2013331496B2 (en) * 2012-10-16 2017-07-27 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ROR-gamma-t
UY35174A (es) 2012-12-06 2014-06-30 Glaxo Group Ltd Nuevos moduladores del receptor huerfano gamma relacionado con retinoides
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
EP3060553A4 (en) 2013-10-25 2017-03-29 Glaxosmithkline LLC Novel compounds
WO2015061686A2 (en) 2013-10-25 2015-04-30 St. Jude Children's Research Hospital, Inc. Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer
CN106660999A (zh) 2014-05-28 2017-05-10 葛兰素史密斯克莱知识产权发展有限公司 新化合物
EA032272B1 (ru) 2014-05-28 2019-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новые соединения
EP3148975B1 (en) 2014-05-28 2018-11-28 GlaxoSmithKline Intellectual Property Development Limited Piperazine derivatives as ror-gamma modulators

Also Published As

Publication number Publication date
CN107001342A (zh) 2017-08-01
JP2017519738A (ja) 2017-07-20
WO2015180614A1 (en) 2015-12-03
JP6522665B2 (ja) 2019-05-29
AU2015267911A1 (en) 2016-12-01
EA201692395A1 (ru) 2017-03-31
SG11201609722UA (en) 2016-12-29
US20170101399A1 (en) 2017-04-13
PH12016502331A1 (en) 2017-02-06
DOP2016000311A (es) 2017-02-28
CN107001342B (zh) 2020-02-07
PE20170137A1 (es) 2017-03-05
CA2953637A1 (en) 2015-12-03
MX2016015631A (es) 2017-04-25
KR20170008852A (ko) 2017-01-24
ES2716966T3 (es) 2019-06-18
EP3148987B1 (en) 2019-01-02
EP3148987A4 (en) 2017-11-15
IL248983A0 (en) 2017-01-31
EP3148987A1 (en) 2017-04-05
CA2953637C (en) 2022-11-29
EA032272B1 (ru) 2019-05-31
US9868724B2 (en) 2018-01-16
AU2015267911B2 (en) 2017-10-26
CR20160549A (es) 2017-04-28

Similar Documents

Publication Publication Date Title
CL2015003569A1 (es) “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2016002772A1 (es) Composiciones de insulina de rápida acción
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2016000381A1 (es) Compuestos antivirales
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CR20160419A (es) Nuevos compuestos biciclicos
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
MX386298B (es) Composicion farmaceutica que comprende adalimumab.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2016002678A1 (es) “compuestos derivados de heteroarilo, ligantes d1; composición farmacéutica que los comprende; útiles en el tratamiento de enfermedades del snc, autoinmune, metabólicas, entre otras”. pct